Kindeva Drug Delivery, a drug delivery device contract development and manufacturing organisation, has received a £33 million grant from the Life Sciences Innovation Manufacturing Fund. 

The funds enhance Kindeva’s capability to manufacture the next generation of green inhalers and to deliver ever-evolving therapies for respiratory diseases worldwide. 

Kindeva’s Global CCO David Stevens, said: “This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the U.K., as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products. This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”

Charnwood Campus Science, Innovation and Technology Park, Loughborough, where the R&D arm of Kindeva is based is also making strides in its decarbonisation efforts to further reduce their carbon emissions in the march toward achieving net zero.

Gosia Khrais, commercial director, Charnwood Campus, said: “As an organisation that is becoming more and more important to the success of the life sciences sector in the region, we take our ESG responsibility very seriously. All construction projects that involve recommissioning of existing or design and build of new buildings prioritise decarbonisation and net zero. The labs and offices available for rent on Charnwood Campus offer great credentials in terms of progress made towards net zero. I would like to encourage anyone who is currently looking for space within a thriving and innovative environment to reach out to us. We will be thrilled to offer a tour round this fantastic science park.”